D593 Task 1 Global Health Issue Analysis Example

Resistance Travels Too: Antimicrobial Resistance as a Global Health Problem Shaped by Globalization, Economics and Environment, and the Agencies Working Against It

Student Name

Leavitt School of Health, Western Governors University

D593: Global Health, Task 1

Course Instructor

Month Day, Year

Resistance Travels Too: Antimicrobial Resistance as a Global Health Problem Shaped by Globalization, Economics and Environment, and the Agencies Working Against It

The Problem

Antimicrobial resistance occurs when bacteria and other microbes change so that the medicines used to treat them no longer work. It turns routine infections into dangerous ones and makes surgery, cancer treatment and childbirth riskier. A comprehensive global analysis estimated that in 2019, 1.27 million deaths were directly attributable to bacterial resistance and 4.95 million deaths were associated with it, with the highest death rates in western sub-Saharan Africa and the lowest in Australasia (Antimicrobial Resistance Collaborators, 2022). This paper analyzes how globalization affects the problem, how economic and environmental factors shape outcomes in different countries and how international initiatives and agencies respond.

Globalization: How It Spreads Resistance

Globalization moves resistant bacteria as efficiently as it moves people and goods. International travel is the clearest example. In a study of 1,847 Dutch travelers who carried no resistant gut bacteria of a common type before leaving, 34.3% acquired them during international travel, including 75.1% of those who visited southern Asia; some carried the bacteria for months after returning, and a small share passed them to household members (Arcilla et al., 2017). Medical tourism, migration and global food trade add further routes. Resistance genes that emerge in one hospital or farm can appear on another continent within months.

Global supply chains also matter. Much of the world's antibiotic supply is manufactured in a small number of countries, and pollution from some manufacturing sites has released antibiotics into rivers, creating conditions where resistance can develop. Global markets for meat have encouraged intensive farming, in which antibiotics have been used to promote growth or prevent disease in crowded animals.

Globalization: How It Helps

Globalization also provides the tools to fight resistance. Surveillance data from dozens of countries can now be pooled, allowing researchers to estimate the global burden and identify the most dangerous combinations of pathogens and drugs. Scientific collaboration speeds the development of new antibiotics, vaccines and diagnostics, and international funding supports laboratory capacity in countries that had none. Global agreements, discussed below, would not be possible without the institutions that globalization built. Even travel, a route of spread, has helped: outbreaks detected in returning travelers have alerted health authorities to resistance emerging in places with little local surveillance.

Economic and Environmental Factors

Economic and environmental conditions shape outcomes more than many people expect. An analysis of resistance across countries found that, after accounting for multiple factors together, better infrastructure and better governance were associated with lower resistance, while antibiotic consumption was not significantly associated with it; the authors concluded that the spread of resistant strains is the dominant factor and that improving sanitation, clean water and governance is necessary to reduce resistance (Collignon et al., 2018).

These findings explain why the burden falls hardest on low-resource settings. Where sewage is untreated and clean water is scarce, resistant bacteria spread from person to person through the environment. Where health systems are underfunded, antibiotics are often sold without prescription and laboratories to guide treatment are rare, so broad-spectrum drugs are used when narrower ones would do. Where public spending is low, people may buy partial courses they can afford. None of this is a reason to blame poorer countries: intensive antibiotic use in medicine and agriculture spread from high-income countries, and hospitals everywhere select for resistant organisms.

How Initiatives and Agencies Respond

The World Health Organization leads the human health response. Its Global Action Plan on Antimicrobial Resistance, adopted in 2015, asks every country to develop a national action plan, and its Global Antimicrobial Resistance and Use Surveillance System collects standardized data from participating countries.

Because resistance moves among people, animals and the environment, the response follows a One Health approach. The World Health Organization works with the Food and Agriculture Organization of the United Nations, the intergovernmental animal health organization known as WOAH and the United Nations' environment agency, UNEP, in a joint partnership that coordinates action on antibiotic use in agriculture, surveillance in animals and environmental contamination.

Political commitments have followed. In 2024, the United Nations General Assembly adopted a political declaration on antimicrobial resistance with a target to reduce global deaths associated with it. Funding programs support laboratories and surveillance in low- and middle-income countries, and partnerships between governments and foundations support the development of new antibiotics for which normal markets offer little profit.

The gaps are real, and they explain why progress has been uneven. National plans in many countries lack funding, surveillance data from low-income settings remain thin, as the global burden analysis itself noted, and new antibiotics reach the market slowly.

Lessons for Public Health Practice

The analysis points to practical lessons for public health professionals in any country. First, stewardship at home matters but is not enough. Hospitals and clinics should continue programs that ensure antibiotics are prescribed only when needed, but the evidence on sanitation and governance means that investments in clean water, infection prevention and public health systems abroad also protect people at home. Second, vaccination is a resistance strategy: every infection prevented by a vaccine is an infection that does not need an antibiotic, and vaccines against pneumococcal disease and typhoid reduce the use of antibiotics as well as illness. Third, travel history belongs in the clinical interview. Because travelers can return carrying resistant bacteria for months, asking about recent international travel and hospitalization abroad helps clinicians choose effective treatment and helps hospitals decide when to screen or isolate. Fourth, surveillance depends on participation. Local health departments and hospital laboratories that report resistance data contribute to the national and global picture that guides policy. Each of these lessons treats resistance as what it is, a shared problem that no country can solve by acting alone.

Conclusion

Antimicrobial resistance shows both faces of globalization: the same connections that carry resistant bacteria across borders make global surveillance, research and cooperation possible. Economic and environmental conditions, especially sanitation and governance, largely determine where the burden falls. Meeting the problem requires more than prescribing fewer antibiotics; it requires the clean water, strong institutions and shared commitments that only international cooperation can build.

References

Antimicrobial Resistance Collaborators. (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. The Lancet, 399(10325), 629-655. https://doi.org/10.1016/S0140-6736(21)02724-0

Arcilla, M. S., van Hattem, J. M., Haverkate, M. R., Bootsma, M. C. J., van Genderen, P. J. J., Goorhuis, A., Grobusch, M. P., Lashof, A. M. O., Molhoek, N., Schultsz, C., Stobberingh, E. E., Verbrugh, H. A., de Jong, M. D., Melles, D. C., & Penders, J. (2017). Import and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae by international travellers (COMBAT study): A prospective, multicentre cohort study. The Lancet Infectious Diseases, 17(1), 78-85. https://doi.org/10.1016/S1473-3099(16)30319-X

Collignon, P., Beggs, J. J., Walsh, T. R., Gandra, S., & Laxminarayan, R. (2018). Anthropological and socioeconomic factors contributing to global antimicrobial resistance: A univariate and multivariable analysis. The Lancet Planetary Health, 2(9), e398-e405. https://doi.org/10.1016/S2542-5196(18)30186-4